Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02958397

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Sponsor: Southwest Hospital, China

Interventions Anti-CD33-CAR-transduced T cells

Updated 7 times since 2017 Last updated: Jun 23, 2019 Started: Oct 31, 2016 Primary completion: Oct 31, 2019 Completion: Oct 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Myeloid Malignancies, this trial is ongoing. The trial is conducted by Southwest Hospital, China and has accumulated 7 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Jul 2019 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jul 2019 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Southwest Hospital, China

Data source: Southwest Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chongqing, China